BRiEF, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of fondaparinux versus enoxaparin in acute medically ill, non-surgical patients

        Z

NCT00521885    



Studied treatment fondaparinux 2.5mg qd
Control treatment enoxaparin 40mg qd



Patients acute medically ill, non-surgical patients
Group sizes-9 / -9
DVT diagnosis
PE diagnosis



Blindness Inclusion period
Follow-up duration Centers single center
Lost to FU geographical localisation Germany
Primary endpoint Design Parallel groups



EndpointX1N1X0N0TE95% CI PE - -9 - -9 no data Venous thromboembolism or death - -9 - -9 no data VTE - -9 - -9 no data fatal PE - -9 - -9 no data DVT - -9 - -9 no data proximal deep-vein thrombosis - -9 - -9 no data Asymptomatic deep vein thrombosis during follow-up. - -9 - -9 no data Major bleeding during follow-up - -9 - -9 no data Symptomatic deep vein thrombosis during follow-up - -9 - -9 no data All-cause death during follow-up - -9 - -9 no data Symptomatic pulmonary embolism during follow-up - -9 - -9 no data net clinical benefit - -9 - -9 no data Clinically relevant bleeding - -9 - -9 no data0,22,01,0

ClinicalTrial.gov record NCT00521885



Registering number NCT00521885 (see trial on clinicaltrials.gov)
Code Name

 

All trials of fondaparinux

Appears in following systematic reviews: